Investor Relations Contact:
ir@anacor.com
Phone: 650-543-7575
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule therapeutics derived from its novel boron chemistry platform. We currently have five product candidates in clinical development. Our three lead product candidates include two topically administered dermatologic compounds— tavaborole (formerly AN2690) , an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory for the treatment of psoriasis, as well as a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria—GSK2251052, or GSK '052 (formerly referred to as AN3365). In addition, we are developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. We have entered into and are seeking partnerships to expand the therapeutic application and commercial value of our boron chemistry platform.
Feb 15, 2012
Anacor Pharmaceuticals to Present at Upcoming Investor Conferences
Feb 8, 2012
Anacor Pharmaceuticals Announces the Sale of 3.25 Million Shares of Common Stock
View all »Events & Presentations
Mar 7, 2012 at 9:20 AM ET
Cowen and Company 32nd Annual Health Care Conference
Feb 28, 2012 at 8:00 AM ET
RBC Global Healthcare Conference
Receive Email Alerts
Sign up to receive e-mail alerts whenever Anacor posts new information to the site.
